Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Anemia, Refractory, with Excess of Blasts 34Leukemia, Myelomonocytic, Chronic 27Myelodysplastic Syndromes 26Lymphoma, Non-Hodgkin 25Leukemia, Lymphocytic, Chronic, B-Cell 24Hodgkin Disease 21Multiple Myeloma 20Myeloproliferative Disorders 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 19Primary Myelofibrosis 17Lymphoma, Follicular 17Anemia, Aplastic 17Lymphoma, Mantle-Cell 16Leukemia 16Anemia, Refractory 15Lymphoma, B-Cell, Marginal Zone 14Lymphoma 14Leukemia, Myeloid, Chronic-Phase 14Congenital Abnormalities 14Leukemia, Myeloid, Accelerated Phase 12Burkitt Lymphoma 12Waldenstrom Macroglobulinemia 10Polycythemia Vera 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Large-Cell, Immunoblastic 9Leukemia, Myelomonocytic, Juvenile 9Dendritic Cell Sarcoma, Interdigitating 9Leukemia, Biphenotypic, Acute 8

Interventions

Thiotepa 3Melphalan 3Cyclophosphamide 3fludarabine phosphate 2fludarabine 2Busulfan 2Alemtuzumab 2Whole-Body Irradiation 1Tacrolimus 1Muromonab-CD3 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Immunotherapy 1Drug Therapy 1Antilymphocyte Serum 1Antibodies 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytosis × Whole-Body Irradiation × Classical hematology × Clear all
NCT01049854 2018-08-21

CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant

New York Medical College

Phase 2 Completed
20 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Bone Marrow Failure Disorders, Anemia, Sickle Cell, Immunologic Deficiency Syndromes, Leukemia, Lymphoma, Metabolism, Inborn Errors, Histiocytosis, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡